Evidence map›Paper›PMID 41140827›Full record

Observational studyNagoya journal of medical science2025

Influence of renal function on the clinical efficacy of carboplatin plus pemetrexed in patients with non-small cell lung cancer.

Kazuki Komeda, Tetsunari Hase, Toru Hara, Tomoki Kimura, Eiji Kojima, Takashi Abe, Yoshitsugu Horio, Yasuhiro Goto, Futoshi Ushijima, Shohei Watanabe and 9 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Nagoya journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Kazuki KomedaDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Tetsunari HaseDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Toru HaraDepartment of Respiratory Medicine, Anjo Kosei Hospital, Anjo, Japan.
Tomoki KimuraDepartment of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Japan.
Eiji KojimaDepartment of Respiratory Medicine, Komaki City Hospital, Komaki, Japan.
Takashi AbeDepartment of Respiratory Medicine, Ogaki Municipal Hospital, Ogaki, Japan.
Yoshitsugu HorioDepartment of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Yasuhiro GotoDepartment of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
Futoshi UshijimaDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shohei WatanabeDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yuki YamadaDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Tomoya ShimokataDepartment of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
Tetsuya OguriDepartment of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Masashi YamamotoDepartment of Respiratory Medicine, Nagoya Ekisaikai Hospital, Nagoya, Japan.
Kiyoshi YanagisawaDivision of Molecular and Cancer Medicine, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Masahiko AndoCenter for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.
Masashi KondoDepartment of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
Yoshinori HasegawaDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Makoto IshiiDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pemetrexed, a structural antifolate agent that is eliminated via renal excretion, is commonly used to treat non-squamous non-small-cell lung cancer (NS-NSCLC). Although poor renal function is associated with a high incidence of toxicities, the association of high renal function with chemotherapy efficacy and toxicity remains unknown. We aimed to investigate the effect of renal function on the efficacy and toxicity of carboplatin-pemetrexed chemotherapy in patients with NS-NSCLC. We performed a post-hoc analysis of a prospective observational study of carboplatin-pemetrexed treatment in NS-NSCLC patients. Baseline renal function was calculated using the Japanese estimated glomerular filtration rate (eGFR) formula, and the patients were then divided into two groups based on the eGFR: high-eGFR (eGFR ≥ 80 mL/min/1.73 m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungKidneyLung NeoplasmsPemetrexedAgedFemaleGlomerular Filtration RateHumansMaleMiddle AgedProspective StudiesTreatment OutcomeCarboplatinPemetrexedglomerular filtration ratenon-small cell lung cancerpemetrexed

Identifiers

PMID41140827
PMCPMC12549113

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.